Cargando…

Outcomes following retroperitoneal lymph node dissection in postchemotherapy residual masses in advanced testicular germ cell tumors

INTRODUCTION: We aimed to study the outcomes of retroperitoneal lymph node dissection (RPLND) in postchemotherapy residual masses in advanced testicular germ cell tumor (GCT) in the Indian population. PATIENTS AND METHODS: We retrospectively analyzed 35 patients who underwent postchemotherapy RPLND...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Prabhjot, Yadav, Siddharth, Mahapatra, Sanjay, Seth, Amlesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756548/
https://www.ncbi.nlm.nih.gov/pubmed/26941493
http://dx.doi.org/10.4103/0970-1591.173102
_version_ 1782416355555803136
author Singh, Prabhjot
Yadav, Siddharth
Mahapatra, Sanjay
Seth, Amlesh
author_facet Singh, Prabhjot
Yadav, Siddharth
Mahapatra, Sanjay
Seth, Amlesh
author_sort Singh, Prabhjot
collection PubMed
description INTRODUCTION: We aimed to study the outcomes of retroperitoneal lymph node dissection (RPLND) in postchemotherapy residual masses in advanced testicular germ cell tumor (GCT) in the Indian population. PATIENTS AND METHODS: We retrospectively analyzed 35 patients who underwent postchemotherapy RPLND at our institute after primary (29 patients) or salvage (6 patients) chemotherapy over a period of 9 years (June 2003 to July 2012). RESULTS: The mean age of our patients was 26.8 years. 18 (51.42%) presented with primary tumor in the right testis and 3 (8.51%) had bilateral tumors. Mixed GCT was the most common histology among 19 (54.3%) patients. 14 (40%) patients had the residual mass in para-aortic location, which was the most common site. 14 (40%) patients required an adjunctive procedure, most commonly nephrectomy which was required in 9 out of 14 (25.7%). We recorded 25 complications, mostly Clavien-Dindo grade II. Histopathology of residual mass was necrosis in 17 (48.57%), teratoma in 12 (34.28%), and viable tumor in 6 (17.14%) patients. CONCLUSION: Nearly half of the patients had either teratoma or viable tumor, thus justifying the surgical resection of postchemotherapy residual mass. Although nearly half of the patients had complications, they were adequately managed and there was no mortality. Thus, postchemotherapy RPLND can be a useful procedure in multimodality approach to GCT in carefully selected patients.
format Online
Article
Text
id pubmed-4756548
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-47565482016-03-03 Outcomes following retroperitoneal lymph node dissection in postchemotherapy residual masses in advanced testicular germ cell tumors Singh, Prabhjot Yadav, Siddharth Mahapatra, Sanjay Seth, Amlesh Indian J Urol Original Article INTRODUCTION: We aimed to study the outcomes of retroperitoneal lymph node dissection (RPLND) in postchemotherapy residual masses in advanced testicular germ cell tumor (GCT) in the Indian population. PATIENTS AND METHODS: We retrospectively analyzed 35 patients who underwent postchemotherapy RPLND at our institute after primary (29 patients) or salvage (6 patients) chemotherapy over a period of 9 years (June 2003 to July 2012). RESULTS: The mean age of our patients was 26.8 years. 18 (51.42%) presented with primary tumor in the right testis and 3 (8.51%) had bilateral tumors. Mixed GCT was the most common histology among 19 (54.3%) patients. 14 (40%) patients had the residual mass in para-aortic location, which was the most common site. 14 (40%) patients required an adjunctive procedure, most commonly nephrectomy which was required in 9 out of 14 (25.7%). We recorded 25 complications, mostly Clavien-Dindo grade II. Histopathology of residual mass was necrosis in 17 (48.57%), teratoma in 12 (34.28%), and viable tumor in 6 (17.14%) patients. CONCLUSION: Nearly half of the patients had either teratoma or viable tumor, thus justifying the surgical resection of postchemotherapy residual mass. Although nearly half of the patients had complications, they were adequately managed and there was no mortality. Thus, postchemotherapy RPLND can be a useful procedure in multimodality approach to GCT in carefully selected patients. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC4756548/ /pubmed/26941493 http://dx.doi.org/10.4103/0970-1591.173102 Text en Copyright: © 2016 Indian Journal of Urology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Singh, Prabhjot
Yadav, Siddharth
Mahapatra, Sanjay
Seth, Amlesh
Outcomes following retroperitoneal lymph node dissection in postchemotherapy residual masses in advanced testicular germ cell tumors
title Outcomes following retroperitoneal lymph node dissection in postchemotherapy residual masses in advanced testicular germ cell tumors
title_full Outcomes following retroperitoneal lymph node dissection in postchemotherapy residual masses in advanced testicular germ cell tumors
title_fullStr Outcomes following retroperitoneal lymph node dissection in postchemotherapy residual masses in advanced testicular germ cell tumors
title_full_unstemmed Outcomes following retroperitoneal lymph node dissection in postchemotherapy residual masses in advanced testicular germ cell tumors
title_short Outcomes following retroperitoneal lymph node dissection in postchemotherapy residual masses in advanced testicular germ cell tumors
title_sort outcomes following retroperitoneal lymph node dissection in postchemotherapy residual masses in advanced testicular germ cell tumors
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756548/
https://www.ncbi.nlm.nih.gov/pubmed/26941493
http://dx.doi.org/10.4103/0970-1591.173102
work_keys_str_mv AT singhprabhjot outcomesfollowingretroperitoneallymphnodedissectioninpostchemotherapyresidualmassesinadvancedtesticulargermcelltumors
AT yadavsiddharth outcomesfollowingretroperitoneallymphnodedissectioninpostchemotherapyresidualmassesinadvancedtesticulargermcelltumors
AT mahapatrasanjay outcomesfollowingretroperitoneallymphnodedissectioninpostchemotherapyresidualmassesinadvancedtesticulargermcelltumors
AT sethamlesh outcomesfollowingretroperitoneallymphnodedissectioninpostchemotherapyresidualmassesinadvancedtesticulargermcelltumors